- Email: [email protected]
Electropure granted ion-exchange patent
NEWS Editorial Office: Elsevier Advanced Technology, P O Box 150, Kidlington Oxford OX5 1AS, UK Tel: +44 (0)1865 843676 Fax: +44 (0)1865 843971 E-mail: [email protected]
Editor: Helen Long
Contributing Editor: Simon Atkinson Tel/Fax: +44 (0)1608 641631 E-mail: [email protected]
Production Coordinator: Ben Pelling Editorial advisory board: Dr P Ball (Pall Europe), Dr D Bessarabov (Kvaerner Chemetics, A Division of Kvaerner Canada Inc, Canada), Prof. M Cheryan (University of Illinois at Urbana-Champaign), Prof. A Fane (University of New South Wales), Dr T Franken (Membrane Application Centre Twente), Dr E Gobina (Robert Gordon University), Dr A Merry (PCI Membrane Systems), Prof. M Nyström (Lappeenranta University of Technology), Dr G Pearce (Kalsep), Dr P Pfromm (Institute of Paper Science & Technology, GA, USA), Dr R Philpott (Whatman International), Dr A Turner (AEA Technology), Prof. R Wakeman (Loughborough University of Technology), Prof. A Yaroshchuk (Ukrainian Academy of Sciences). Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: [email protected]. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.nl), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
Hyflux and Ondeo awarded PUB contract The Public Utilities Board (PUB) of Singapore has awarded a contract for a build, own and operate desalination plant to Singspring, a consortium comprising Hyflux Ltd and Ondeo. To be built in Tuas, Singapore, the new plant, which will be capable of producing 136 000 m3 desalinated water a day, is scheduled to start supplying water during the second half of 2005. It will use reverse osmosis. Hyflux is taking a 70% stake in the consortium, while Ondeo will assume the balance. With this increased stake, the Hyflux Group says that it is expected to win major contracts from the engineering, construction and procurement contractor for the project. Most of the contract value will lie in the membrane systems that it is supplying. These will be built locally using its proprietary membrane technology. Revenue from this project will be realized over a period of 2.5 years. Commenting on this award, Ms Olivia Lum, Hyflux Group chief executive officer and president, said: “This is our biggest project to date. It is a strategic project for us and so it is logical for us to take a majority interest. It will position us to be a strategic player in large municipal projects in Singapore and beyond.” For more information, contact: Hyflux Group, 40 Changi South Street, 1 Singapore 486764. Tel: +65 6214 0777, Fax: +65 6214 1211, Email: sales@ hyflux.com.
GEA offers spiral-wound RO plants In the USA, GEA Filtration has introduced sanitary reverse osmosis (RO) plants in a 20 cm (8 inch) spiral-wound configuration. The company says that this new sanitary design offers the same modular, cost-effective plant con-
struction and operating advantages as its spiral plants with a smaller diameter, but offers the added advantages of a more compact design, lower capital cost, reduced membrane replacement costs and no adverse effects on plant cleanliness or sanitation. The membrane area is delivered in the larger 20-cm (8-inch) diameter sanitary spiral-wound format, and it is housed in 20-cm (8-inch) sanitary vessels. It is this increased membrane packing density that creates the compact design, saving valuable floor space, says the company. Operating costs are further reduced by the improved compact design and reduced plant hold-up volume. This results in a reduction in water consumption, and associated wastewater treatment costs, as well as a reduction in the consumption of clean-in-place chemicals. The plants are constructed to 3A sanitary standards for compliance with US Department of Agriculture and local regulatory health agency requirements. According to GEA, exhaustive cleaning and sanitation trials on several commercially delivered plants have verified that they operate with no compromise to cleanliness and sanitation. GEA says that with several plants now delivered and in operation, and several more in the pipeline, sufficient demand has been created to ensure that membrane elements in the 20-cm (8-inch) sanitary configuration are widely available from a number of manufacturers and can be supplied directly from the company’s stock. For more information, contact: GEA Filtration, 1600 O’Keefe Road, Hudson, WI 54016, USA. Tel: +1 715 386 9371, Fax: +1 715 386 9376, Email: [email protected].
Electropure granted ionexchange patent Electropure Inc of Laguna Hills, California, USA, has been granted a US Patent for what it claims is a novel process that is used to make improved ion-exchange membranes, an integral part of its
electrodeionization (EDI) water purification technology. The patent (number US 6503957) describes a low temperature method for making polypropylene-based ion-exchange membranes, which enable the efficient removal of impurity ions like sodium, chloride and silica from water. Electropure says that its process for making membranes is also environmentally friendly, using no solvents of any kind, and it is ideal for systems that go into EDI pharmaceutical applications. Michael Snow, general manager of the EDI subsidiary, says that this patent enables Electropure to offer high quality EDI products, and the patented process lets the company manufacture ionexchange membranes continuously at a reasonable cost, and with strict quality control. Electropure designs, manufactures and markets proprietary water purification equipment and laserbased technology for detecting and identifying microorganisms in real time. For more information, contact: Electropure Inc, 23456 South Pointe Drive, Laguna Hills, CA 92653, USA. Tel: +1 949 770 9347, Fax: +1 949 770 9209. Email: [email protected].
Georgia and DND select Zenon technology Zenon Environmental Inc’s technologies are set to be used in a wastewater treatment project in Georgia, USA, and by Canada’s Department of National Defence (DND). Zenon has been selected by Gwinnett County to supply its patented ZeeWeed membrane technology to F. Wayne Hill Water Resources Center in Georgia. The company negotiated an agreement with the county for around C$30 million, and it expects to receive the final purchase order by July 2003. The Gwinnett County F. Wayne Hill Water Resources Center is a water reclamation and processing facility that is located just north of Atlanta, Georgia. Plans are under
Membrane Technology February 2003
Editor: Helen Long
Contributing Editor: Simon Atkinson Tel/Fax: +44 (0)1608 641631 E-mail: [email protected]
Production Coordinator: Ben Pelling Editorial advisory board: Dr P Ball (Pall Europe), Dr D Bessarabov (Kvaerner Chemetics, A Division of Kvaerner Canada Inc, Canada), Prof. M Cheryan (University of Illinois at Urbana-Champaign), Prof. A Fane (University of New South Wales), Dr T Franken (Membrane Application Centre Twente), Dr E Gobina (Robert Gordon University), Dr A Merry (PCI Membrane Systems), Prof. M Nyström (Lappeenranta University of Technology), Dr G Pearce (Kalsep), Dr P Pfromm (Institute of Paper Science & Technology, GA, USA), Dr R Philpott (Whatman International), Dr A Turner (AEA Technology), Prof. R Wakeman (Loughborough University of Technology), Prof. A Yaroshchuk (Ukrainian Academy of Sciences). Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: [email protected]. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.nl), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
Hyflux and Ondeo awarded PUB contract The Public Utilities Board (PUB) of Singapore has awarded a contract for a build, own and operate desalination plant to Singspring, a consortium comprising Hyflux Ltd and Ondeo. To be built in Tuas, Singapore, the new plant, which will be capable of producing 136 000 m3 desalinated water a day, is scheduled to start supplying water during the second half of 2005. It will use reverse osmosis. Hyflux is taking a 70% stake in the consortium, while Ondeo will assume the balance. With this increased stake, the Hyflux Group says that it is expected to win major contracts from the engineering, construction and procurement contractor for the project. Most of the contract value will lie in the membrane systems that it is supplying. These will be built locally using its proprietary membrane technology. Revenue from this project will be realized over a period of 2.5 years. Commenting on this award, Ms Olivia Lum, Hyflux Group chief executive officer and president, said: “This is our biggest project to date. It is a strategic project for us and so it is logical for us to take a majority interest. It will position us to be a strategic player in large municipal projects in Singapore and beyond.” For more information, contact: Hyflux Group, 40 Changi South Street, 1 Singapore 486764. Tel: +65 6214 0777, Fax: +65 6214 1211, Email: sales@ hyflux.com.
GEA offers spiral-wound RO plants In the USA, GEA Filtration has introduced sanitary reverse osmosis (RO) plants in a 20 cm (8 inch) spiral-wound configuration. The company says that this new sanitary design offers the same modular, cost-effective plant con-
struction and operating advantages as its spiral plants with a smaller diameter, but offers the added advantages of a more compact design, lower capital cost, reduced membrane replacement costs and no adverse effects on plant cleanliness or sanitation. The membrane area is delivered in the larger 20-cm (8-inch) diameter sanitary spiral-wound format, and it is housed in 20-cm (8-inch) sanitary vessels. It is this increased membrane packing density that creates the compact design, saving valuable floor space, says the company. Operating costs are further reduced by the improved compact design and reduced plant hold-up volume. This results in a reduction in water consumption, and associated wastewater treatment costs, as well as a reduction in the consumption of clean-in-place chemicals. The plants are constructed to 3A sanitary standards for compliance with US Department of Agriculture and local regulatory health agency requirements. According to GEA, exhaustive cleaning and sanitation trials on several commercially delivered plants have verified that they operate with no compromise to cleanliness and sanitation. GEA says that with several plants now delivered and in operation, and several more in the pipeline, sufficient demand has been created to ensure that membrane elements in the 20-cm (8-inch) sanitary configuration are widely available from a number of manufacturers and can be supplied directly from the company’s stock. For more information, contact: GEA Filtration, 1600 O’Keefe Road, Hudson, WI 54016, USA. Tel: +1 715 386 9371, Fax: +1 715 386 9376, Email: [email protected].
Electropure granted ionexchange patent Electropure Inc of Laguna Hills, California, USA, has been granted a US Patent for what it claims is a novel process that is used to make improved ion-exchange membranes, an integral part of its
electrodeionization (EDI) water purification technology. The patent (number US 6503957) describes a low temperature method for making polypropylene-based ion-exchange membranes, which enable the efficient removal of impurity ions like sodium, chloride and silica from water. Electropure says that its process for making membranes is also environmentally friendly, using no solvents of any kind, and it is ideal for systems that go into EDI pharmaceutical applications. Michael Snow, general manager of the EDI subsidiary, says that this patent enables Electropure to offer high quality EDI products, and the patented process lets the company manufacture ionexchange membranes continuously at a reasonable cost, and with strict quality control. Electropure designs, manufactures and markets proprietary water purification equipment and laserbased technology for detecting and identifying microorganisms in real time. For more information, contact: Electropure Inc, 23456 South Pointe Drive, Laguna Hills, CA 92653, USA. Tel: +1 949 770 9347, Fax: +1 949 770 9209. Email: [email protected].
Georgia and DND select Zenon technology Zenon Environmental Inc’s technologies are set to be used in a wastewater treatment project in Georgia, USA, and by Canada’s Department of National Defence (DND). Zenon has been selected by Gwinnett County to supply its patented ZeeWeed membrane technology to F. Wayne Hill Water Resources Center in Georgia. The company negotiated an agreement with the county for around C$30 million, and it expects to receive the final purchase order by July 2003. The Gwinnett County F. Wayne Hill Water Resources Center is a water reclamation and processing facility that is located just north of Atlanta, Georgia. Plans are under
Membrane Technology February 2003